Filing summary
Entity and period: The supplied filing is ChromaDex Corporation’s Form 10-K for the fiscal year ended December 31, 2020, filed March 12, 2021. This does not match the request metadata naming Niagen Bioscience, Inc.; verify the intended issuer. The filing reports full-year results, not a standalone 2020 fourth quarter.
Business context
ChromaDex describes itself as a bioscience company focused on healthy aging. Its three segments are consumer products, led by TRU NIAGEN; ingredient sales, including NIAGEN nicotinamide riboside (NR); and analytical reference standards and services. Consumer products were the largest segment and accounted for about 79% of 2020 sales.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Net sales | $59.3 million | $46.3 million |
| Gross profit | $35.3 million | $25.8 million |
| Gross margin | 59.5% | 55.7% |
| Operating loss | $19.9 million | $31.3 million |
| Net loss | $19.9 million | $32.1 million |
| Basic and diluted loss per share | $0.33 | $0.56 |
| Cash used in operating activities | $10.6 million | $20.4 million |
Sales increased 28%. Consumer products sales grew 31% to $47.1 million; ingredients sales rose 48% to $9.2 million; analytical reference standards and services sales fell 26% to $3.0 million. Gross margin improved as consumer and ingredient product costs declined, while the analytical segment’s gross profit dropped to $0.1 million amid lower sales and underutilized fixed costs.
Sales and marketing expense increased 15% to $20.9 million, primarily from consumer marketing and staffing. Research and development expense decreased 16% to $3.7 million. General and administrative expense decreased 11% to $30.4 million, reflecting lower legal and bad debt expense. Legal expense was $8.6 million, down from $11.3 million; 2019 included a $2.2 million bad-debt charge related to Elysium.
At year-end, cash and cash equivalents were $16.7 million; current assets were $32.2 million and current liabilities $16.5 million. Inventory was $11.7 million and accounts payable $9.4 million. The company reported working capital of $4.9 million using its stated measure of trade receivables plus inventory less accounts payable, rather than the conventional current-assets-minus-current-liabilities calculation.
No borrowings were outstanding under the $7.0 million Western Alliance Bank revolving line at December 31, 2020. The facility is secured by substantially all current and future personal property, including intellectual property, and includes financial and other covenants. Lease obligations were approximately $1.6 million operating and $0.1 million finance. The company reported no material off-balance-sheet arrangements.
Changes, outlook and management commentary
- Consumer and ingredient growth more than offset the decline in analytical services. The analytical segment was affected by the 2019 spin-off of its regulatory consulting unit and COVID-related impacts.
- Management said ecommerce continued to perform relatively well during COVID-19, while international retail sales were affected by store closures and reduced hours. Supplier shipment delays occurred, but management reported adequate inventory and no major supply-chain disruption.
- Management expected year-end cash, expected operating cash generation, a subsequent $25.0 million equity financing and the available bank line to fund projected plans for at least 12 months from the report’s issuance. It also said additional capital may be needed for longer-term objectives. The $25.0 million common-stock financing occurred after year-end; the company also received about $3.4 million from option exercises through March 5, 2021. These are subsequent events, not year-end cash.
- The Nestlé supply agreement generated a $1.0 million product-launch payment in 2020, in addition to a $4.0 million upfront payment received in 2019. The fees are treated as advance payments for future performance obligations; $0.4 million of deferred revenue was recognized in 2020, and deferred revenue was $4.4 million at year-end.
- Management reported a history of annual losses and no annual profitability to date. No formal revenue or earnings guidance is provided in the supplied filing text.
Risks, contingencies and unusual items
- Litigation: The company is engaged in extensive litigation with Elysium across California, New York and Delaware, including patent disputes. It said it could not reasonably estimate potential loss or range of loss and recorded no potential-loss accrual for the described Elysium matters.
- Customer dispute: Rejuvenation Therapeutics requested a refund of about $1.6 million of purchased NIAGEN, alleging contract breaches. ChromaDex recorded a $0.5 million return liability and said it did not expect the matter to be material.
- Regulatory warning: The FDA and FTC issued a November 2020 warning letter concerning company statements about NR and COVID-19. The company disputed the agencies’ characterization, removed certain materials, and stated TRU NIAGEN is not approved to prevent, treat, diagnose or cure COVID-19 or any other disease.
- Controls: Management concluded that disclosure controls and internal control over financial reporting were ineffective at December 31, 2020 because of an unremediated material weakness. The weakness involved failure to timely disclose and accrue for the Rejuvenation customer claim in the third-quarter 2020 filing. Management expected remediation before year-end 2021.
- Concentration and supply: A.S. Watson, a related party, represented 13% of 2020 sales. One vendor represented 39.7% of year-end accounts payable. W.R. Grace was the exclusive NR manufacturer; the supply agreement was scheduled to expire December 31, 2021, subject to negotiated renewal.
- Commitments: Purchase obligations totaled $17.3 million, all due in 2021. The company also disclosed an unresolved $1.6 million sublicense-fee demand from a licensor, which it disputed and did not expect to be material.
Most important facts for investors to verify
- Confirm the intended issuer: the filing identifies ChromaDex Corporation (Nasdaq: CDXC), not Niagen Bioscience, Inc.
- Review subsequent-period cash, cash burn and financing proceeds, including the $25.0 million equity issuance and dilution from option exercises and outstanding options.
- Track progress on remediating the material weakness and assess whether future filings disclose and record contingencies promptly.
- Monitor Elysium litigation, the Rejuvenation claim, the licensor fee dispute and the Thorne patent challenges; outcomes and possible financial exposure remain uncertain.
- Assess TRU NIAGEN demand, marketing efficiency, retail-channel recovery, customer concentration and dependence on Grace as the exclusive NR supplier.
- Check covenant compliance and the availability and terms of the secured revolving credit facility.